When a health plan labels care as “experimental” or “investigational,” the denial can feel final. In many cases, it is not. These disputes often turn on policy wording, medical evidence, timing, and the way the appeal is built. A person can have serious medical support, published research, and a compelling need for treatment — and still end up with a weak coverage record if key pieces are missing.
In this post, you’ll learn six common mistakes that can undercut an otherwise persuasive coverage argument, why insurers and reviewers focus on those gaps, and how attorneys often help frame these disputes more effectively. If you want broader background on how these denials work, it may help to start with this overview of how plans frame experimental-treatment exclusions and evidence disputes.
<aside> 💡 Scroll to the bottom for every post in this series.
</aside>
Under federal appeals rules, denials involving medical judgment can qualify for internal appeal and, in many plans, independent external review. That includes denials based on a determination that a treatment is experimental or investigational. HealthCare.gov explains that external review is available for denials involving medical necessity and for decisions that classify treatment as experimental or investigational. The Centers for Medicare & Medicaid Services similarly notes that adverse benefit determinations involving medical judgment can include an insurer’s conclusion that a treatment is experimental or investigational. The U.S. Department of Labor also explains that group health claimants generally get at least 180 days to appeal a denial and may have external review rights if the internal appeal is denied.
That framework matters because these cases are rarely won by emotion alone. They are often decided on the record: the policy language, the denial rationale, the physician support, the cited literature, and whether the claimant addressed the exact basis for the exclusion. In general terms, a strong appeal is often less about saying the treatment is promising and more about showing the plan’s stated reason for denial does not fit the facts, the science, or the plan text.
One of the most common problems is treating the denial like a general medical disagreement instead of a contract dispute tied to a specific definition.
Many plans do not simply deny care because it is “new.” They rely on detailed policy terms: lack of FDA approval for the particular use, insufficient evidence in peer-reviewed literature, absence of consensus guidelines, failure to satisfy a plan-defined standard of medical necessity, or classification as investigational under internal criteria. The denial notice is supposed to give specific reasons and explain the appeal process. Under Department of Labor claims-procedure guidance, denial notices for group health claims are expected to provide concrete reasons and, where medical judgment is involved, plans deciding appeals generally consult an appropriate health care professional. See the DOL’s benefit claims procedure regulation guidance and claims filing overview.
Here’s what this often means in practice: if the plan says the treatment is excluded because it lacks sufficient evidence for this diagnosis, this patient profile, and this line of therapy, an appeal that only says “the treatment is widely used” may leave the core issue unanswered.
A more effective record often ties each piece of evidence back to the policy’s own language:
This is one reason these matters often overlap with broader evidence and wording battles discussed in this deeper explainer on policy language and emerging-treatment denials.
Another mistake is relying too heavily on broad online materials — news stories, advocacy pages, clinic marketing, social posts, or even legitimate research that is not tied closely enough to the patient’s condition.
Independent reviewers and plan fiduciaries are often looking for patient-specific relevance. General enthusiasm around a therapy may not answer whether the treatment is appropriate for this diagnosis, stage of disease, prior treatment history, biomarker profile, age group, comorbidities, or urgency level.